Suppliers / Symbiotec Pharmalab

Symbiotec Pharmalab

India Updated 9 July 2026

Symbiotec Pharmalab is an API manufacturer based in India. It holds 49 active US drug master files across a filed portfolio of 23 molecules. Its GMP standing is certified by MFDS (Korea) and EMA. Its most recent recorded inspection, by US FDA, closed on 30 September 2022 as VAI. Customs aggregates show $29.6M of exports covering 312 molecules to 39 destinations in 2025.

49
active US DMFs
0
valid CEPs
2
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 30 September 2022 VAI US FDA
  • 22 October 2019 VAI US FDA
  • 13 September 2019 VAI US FDA
  • 12 May 2017 VAI US FDA
  • 5 May 2017 VAI US FDA
  • 10 April 2015 NAI US FDA
  • 25 July 2014 NAI US FDA
  • 20 January 2012 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Dhar, India 3009298759
Indore, India 3005122933

What they file, and where

Molecule Regulators Docs
Methylprednisolone SFDA (Saudi Arabia), US FDA 8
Prednisolone SFDA (Saudi Arabia), US FDA 7
Betamethasone US FDA 6
Hydrocortisone SFDA (Saudi Arabia), US FDA 6
Testosterone US FDA 5
Mometasone Furoate SFDA (Saudi Arabia), US FDA 3
Clobetasol Propionate US FDA 2
Deflazacort SFDA (Saudi Arabia), US FDA 2
Dexamethasone US FDA 2
Flumethasone US FDA 2
Show all 23 molecules on file
Progesterone SFDA (Saudi Arabia), US FDA 2
Desogestrel US FDA 1
Desoximetasone US FDA 1
Drospirenone US FDA 1
Estradiol US FDA 1
Ethinylestradiol US FDA 1
Halobetasol Propionate US FDA 1
Hydroxyprogesterone US FDA 1
Levonorgestrel US FDA 1
Prasterone US FDA 1
Testosterone Undecanoate US FDA 1
Triamcinolone US FDA 1
Ulobetasol SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Show 4 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MFDS (Korea) None 2
EMA None 2

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $2.8M 16
2025 Not reported $29.6M 39
2024 Not reported $15.0M 32
2023 Not reported $15.8M 43

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Symbiotec Pharmalab comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 30 September 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts